Recurrence and occurrence of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment for chronic hepatitis C in patients with advanced liver disease: Turkish multi-center early access program
dc.authorid | Çavuş, Bilger/0000-0003-2203-4255 | |
dc.authorid | EROL, CİHAN/0000-0003-3155-8798 | |
dc.authorid | Karasu, Zeki/0000-0002-4974-7944 | |
dc.authorwosid | KIYICI, Murat/AAI-4213-2021 | |
dc.authorwosid | Kaymakoglu, Sabahattin/AAT-2362-2020 | |
dc.authorwosid | Çavuş, Bilger/N-5492-2019 | |
dc.authorwosid | EROL, CİHAN/GWU-8797-2022 | |
dc.authorwosid | Karasu, Zeki/W-1176-2018 | |
dc.contributor.author | Idilman, R. | |
dc.contributor.author | Demir, M. | |
dc.contributor.author | Aladag, M. | |
dc.contributor.author | Kaymakoglu, S. | |
dc.contributor.author | Erol, C. | |
dc.contributor.author | Cavus, B. | |
dc.contributor.author | Iliaz, R. | |
dc.date.accessioned | 2024-08-04T21:00:59Z | |
dc.date.available | 2024-08-04T21:00:59Z | |
dc.date.issued | 2018 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description | International Liver Congress (ILC) -- APR 11-15, 2018 -- Paris, FRANCE | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | European Assoc Study Liver | en_US |
dc.identifier.endpage | S301 | en_US |
dc.identifier.issn | 0168-8278 | |
dc.identifier.issn | 1600-0641 | |
dc.identifier.startpage | S301 | en_US |
dc.identifier.uri | https://hdl.handle.net/11616/103994 | |
dc.identifier.volume | 68 | en_US |
dc.identifier.wos | WOS:000461068601213 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science Bv | en_US |
dc.relation.ispartof | Journal of Hepatology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | Recurrence and occurrence of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment for chronic hepatitis C in patients with advanced liver disease: Turkish multi-center early access program | en_US |
dc.type | Conference Object | en_US |